Dosage & Administration Drug label Prior authorization Pharmacy Financial assistance

Stelara

(ustekinumab)

0.5 ML ustekinumab 90 MG/ML Injection [Stelara]0.5 ML ustekinumab 90 MG/ML Prefilled Syringe [Stelara]

View 2 more

NO BLACK BOX WARNING

Dosage & administration

Psoriasis Adult Subcutaneous Recommended Dosage :

Weight Range (kilograms)	Dosage Regimen
less than or equal to 100 kg	45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks
greater than 100 kg	90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks

Psoriasis Pediatric Patients (6 to 17 years old) Subcutaneous Recommended Dosage :

Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter.

Weight Range (kilograms)	Dose
less than 60 kg	0.75 mg/kg
60 kg to 100 kg	45 mg
greater than 100 kg	90 mg

Psoriatic Arthritis Adult Subcutaneous Recommended Dosage :

* The recommended dosage is 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks.
* For patients with co-existent moderate-to-severe plaque psoriasis weighing greater than 100 kg, the recommended dosage is 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks.

Psoriatic Arthritis Pediatric (6 to 17 years old) Subcutaneous Recommended Dosage : Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter.

Weight Range (kilograms)	Dosage Regimen
less than 60 kg	0.75 mg/kg
60 kg or more	45 mg
greater than 100 kg with co-existent moderate-to-severe plaque psoriasis	90 mg

Crohn's Disease and Ulcerative Colitis Initial Adult Intravenous Recommended Dosage :

A single intravenous infusion using weight-based dosing:

Weight Range (kilograms)	Recommended Dosage
up to 55 kg	260 mg (2 vials)
greater than 55 kg to 85 kg	390 mg (3 vials)
greater than 85 kg	520 mg (4 vials)

Crohn's Disease and Ulcerative Colitis Maintenance Adult Subcutaneous Recommended Dosage :

A subcutaneous 90 mg dose 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.

drug label

Stelara prescribing information

Contact Medical Science Liaison Report Adverse Event

prior authorization

Stelara prior authorization resources

Most recent Stelara prior authorization forms

View By Payer

Verified: Sep 10, 2023Kaiser Permanente - Mid Atlantic Stelara Prior Authorization Form Mid-Atlantic States

Verified: Oct 02, 2023Blue Cross Blue Shield of Michigan - FEP Stelara Prior Authorization Form (Medical Benefit)

Verified: Sep 28, 2023Blue Cross Blue Shield of North Carolina - Stelara Prior Authorization Form

Verified: Sep 28, 2023Paramount - Stelara Prior Authorization Form

Verified: Sep 28, 2023Independence Blue Cross - Stelara Prior Authorization Form

Verified: Sep 28, 2023Caremark - Stelara Prior Authorization Form

Verified: Sep 28, 2023Cigna - Stelara SQ Prior Authorization Form

Verified: Sep 28, 2023Cigna - Stelara IV Prior Authorization Form

Verified: Sep 28, 2023Blue Cross Blue Shield of North Carolina - Pediatric Plaque Psoriasis Prior Authorization Form

Verified: Sep 26, 2023Blue Cross Blue Shield of Michigan - Stelara SC Prior Authorization Form (Medical Benefit)

OTHERComplete Letter of Medical Necessity

PDFMedication Guide

OTHERLetter of Exception: Crohn's Disease

OTHERLetter of Exception: Ulcerative Colitis

OTHERLetter of Exception: Plaque Psoriasis

OTHERLetter of Exception: Psoriatic Arthritis

PDFPA Checklist

PDFPA Checklist - Spanish

PDFAppeals Considerations Checklist

PDFAppeals Considerations Checklist - Spanish

PDFGastroenterology Enrollment Form

PDFDermatology & Rheumatology Enrollment Form

Learn More

Benefits investigation

PDFGastroenterology Enrollment Form

PDFDermatology & Rheumatology Enrollment Form

Learn More

Reimbursement help (FRM)

OTHERReceive Assistance from an FRM Regarding Reimbursement Information

Learn More

pharmacy

Stelara preferred pharmacy

PDFPharmacy List

financial assistance

Stelara financial assistance options

Co-pay savings program

commercial only

Enroll in Patient Savings Program

PDFGastroenterology Enrollment Form

PDFDermatology & Rheumatology Enrollment Form

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

OTHERBridge Program

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Janssen Patient Assistance Program

Johnson & Johnson Patient Assistance Foundation (JJPAF) Eligibility Check

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Stelara patient education

Getting started on Stelara

BRAND PAGEInstructions For Use: Plaque Psoriasis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

BRAND PAGEInstructions For Use: Psoriatic Arthritis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

BRAND PAGEInstructions For Use: Ulcerative Colitis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

BRAND PAGEInstructions For Use: Crohn's Disease

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

To share resource; ask patient to:

1.Pull out phone

2.Open camera

3.Scan QR code with camera

4.Tap link

Patient toolkit

BRAND PAGEAbout Stelara: Plaque Psoriasis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

OTHERView How to Take Stelara: Plaque Psoriasis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

BRAND PAGEAbout Stelara: Pediatric Plaque Psoriasis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

PDFDoctor Discussion Guide: Plaque Psoriasis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

BRAND PAGEAbout Stelara: Psoriatic Arthritis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

OTHERView How to Take Stelara: Psoriatic Arthritis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

PDFDoctor Discussion Guide: Psoriatic Arthritis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

OTHERPatient Resources: Psoriatic Arthritis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

BRAND PAGEAbout Stelara: Ulcerative Colitis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

OTHERPatient Resources: Ulcerative Colitis

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

BRAND PAGEAbout Stelara: Crohn's Disease

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

OTHERPatient Resources: Crohn's Disease

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Learn More

Other resources

Learn More

Stelara FAQs

Is STELARA® safe to use during pregnancy?Limited data on the use of STELARA® in pregnant women are insufficient to inform a drug-associated risk. Animal studies have not shown any adverse effects, but the background risk of major birth defects and miscarriage for the indicated population(s) is unknown. Pregnant women should only use STELARA® if the potential benefits outweigh the risks.

Is it safe to use STELARA® while breastfeeding?There is no data on the presence of ustekinumab in human milk or the effects on milk production or the breastfed infant. Ustekinumab was present in the milk of lactating monkeys administered ustekinumab. Breastfeeding women should only use STELARA® if the potential benefits outweigh the risks.

Can children use STELARA®?STELARA® is approved for the treatment of moderate to severe plaque psoriasis in pediatric patients 6 to 17 years old, and psoriatic arthritis in pediatric patients 6 to 17 years old. Use in patients less than 6 years of age with psoriasis or psoriatic arthritis or in pediatric patients with Crohn’s disease or ulcerative colitis has not been established.

Is STELARA® safe for geriatric patients?Although no overall differences in safety or efficacy were observed between older and younger patients, the number of patients aged 65 and over is not sufficient to determine whether they respond differently from younger patients. Geriatric patients using STELARA® may have a higher frequency of serious infection, so caution should be used when treating them.

FAQ Data Source

Stelara

Dosage & administration

drug label

Stelara prescribing information

prior authorization

Stelara prior authorization resources

Most recent Stelara prior authorization forms

Benefits investigation

Reimbursement help (FRM)

pharmacy

Stelara preferred pharmacy

financial assistance

Stelara financial assistance options

Co-pay savings program

Bridge program

Foundation programs

patient education

Stelara patient education

Getting started on Stelara

Patient toolkit

Other resources

people also ask

Stelara FAQs